公开(公告)号：US20210008113A1

公开(公告)日：2021-01-14

申请号：US17040519

申请日：2019-03-26

申请人： SYSTIMMUNE, INC. ,  SICHUAN BAILI PHARMACEUTICAL CO. LTD.

发明人： Yi ZHU ,  Ole OLSEN ,  Jahan KHALILI ,  Dong XIA ,  David JELLYMAN ,  Katrina BYKOVA ,  Anne-Marie ROUSSEAU ,  Camilla WANG ,  Zeren GAO ,  Hui HUANG ,  Steven K. LUNDY

IPC分类号： A61K35/17 ,  C12N5/0783 ,  G01N33/574 ,  C07K14/725 ,  C07K14/705 ,  C07K16/28 ,  A61P35/00

摘要： The application provides methods for generating a therapeutic composition. The method includes the steps of providing a cell material comprising a cytotoxic cell, incubating the cell material with a first GNC protein to provide an activated cell composition, wherein the activated cell composition comprises a first therapeutic cell, and formulating the activated cell composition to provide a therapeutic composition, wherein the therapeutic composition is substantially free of exogenous viral and non-viral DNA or RNA. The first GNC protein comprises a first cytotoxic binding moiety and a first cancer targeting moiety, wherein the first cytotoxic binding moiety has a specificity to a first cytotoxic cell receptor and is configured to activate the first cytotoxic cell, and wherein the first cancer targeting moiety has a specificity to a first cancer cell receptor. The first therapeutic cell comprises the first GNC protein bound to the cytotoxic cell through the first cytotoxic cell receptor.

公开(公告)号：US20210024630A1

公开(公告)日：2021-01-28

申请号：US17040513

申请日：2019-03-26

申请人： SYSTIMMUNE, INC. ,  SICHUAN BAIL! PHARMACEUTICAL CO. LTD.

发明人： Yi ZHU ,  Ole OLSEN ,  Dong XIA ,  David JELLYMAN ,  Katrina BYKOVA ,  Anne-Marie ROUSSEAU ,  Bill BRADY ,  Blair RENSHAW ,  Brian KOVACEVICH ,  Yu LIANG ,  Camilla WANG ,  Zeren GAO ,  Hui Huang

IPC分类号： C07K16/28 ,  A61P35/02 ,  C12N5/0783 ,  C12N5/09

摘要： The application provides guidance and navigation control (GNC) proteins. In one embodiment, the guidance and navigation control (GNC) protein, comprising a binding domain for a T cell activating receptor, a binding domain for a tumor associated antigen, a bind domain for an immune checkpoint receptor, and a binding domain for a T cell co-stimulating receptor. The binding domain for the tumor associated antigen is not adjacent to the binding domain for the T cell co-stimulating receptor. In one embodiment, the binding domain for the T cell activating receptor is adjacent to the binding domain for the tumor associated antigen (TAA).